Study ID: NSABP B-58 MonarchE Trial


A Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy Compared to Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Hormone Receptor Positive, HER2-Negative, Breast Cancer

You are enrolled in medical research study of a study drug known as abemaciclib. Eli Lilly and Company and its representatives sponsor, and NSABP Foundation, Inc. in the United States and Canada, are conducting this study. The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research question: Whether the combination of the investigational drug, abemaciclib, plus adjuvant endocrine therapy improves outcomes in subjects with early stage breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) when compared to standard treatment with adjuvant endocrine therapy alone.
Sioux Falls Region
Principal Investigator:
Amy Sanford, MD
Breast - Invasive
Phase III
Active - Open to Accrual